Enliven Therapeutics Inc’s recent filing unveils that its Member of immediate family of Patel Anish acquired Company’s shares for reported $57875.0 on Dec 16 ’24. In the deal valued at $23.15 per share,2,500 shares were bought.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Patel Anish bought 2,500 shares, generating $57,875 in total proceeds.
Before that, Hohl Benjamin sold 5,250 shares. Enliven Therapeutics Inc shares valued at $130,688 were divested by the CHIEF FINANCIAL OFFICER at a price of $24.89 per share. As a result of the transaction, Hohl Benjamin now holds 0 shares, worth roughly $0.0.
BTIG Research initiated its Enliven Therapeutics Inc [ELVN] rating to a Buy in a research note published on December 13, 2024; the price target was $42. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early September with a ‘”a Buy”‘ rating. Robert W. Baird began covering ELVN with “an Outperform” recommendation on June 11, 2024. Mizuho started covering the stock on April 09, 2024. It rated ELVN as “a Buy”.
Price Performance Review of ELVN
On Tuesday, Enliven Therapeutics Inc [NASDAQ:ELVN] saw its stock fall -1.20% to $23.15. Over the last five days, the stock has lost -5.08%. Enliven Therapeutics Inc shares have risen nearly 67.27% since the year began. Nevertheless, the stocks have risen 55.89% over the past one year. While a 52-week high of $30.03 was reached on 10/18/24, a 52-week low of $10.90 was recorded on 03/15/24. SMA at 50 days reached $25.97, while 200 days put it at $22.92.
Levels Of Support And Resistance For ELVN Stock
The 24-hour chart illustrates a support level at 22.55, which if violated will result in even more drops to 21.95. On the upside, there is a resistance level at 23.73. A further resistance level may holdings at 24.30. The Relative Strength Index (RSI) on the 14-day chart is 44.02, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.52, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 61.96%. Stochastics %K at 33.51% indicates the stock is a holding.
How much short interest is there in Enliven Therapeutics Inc?
A steep rise in short interest was recorded in Enliven Therapeutics Inc stocks on 2024-11-29, growing by 2203.0 shares to a total of 6.91 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 6.91 million shares. There was a rise of 0.03%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 29, 2023 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $27 price target.
